Alzheimer’s Disease Market Will More Than Double to $11.3 Billion by 2021, says GBI Research
The Alzheimer’s disease market will more than double from about $5 billion in 2014 to an estimated $11.3 billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11.8%, according to business intelligence provider GBI Research.
The company’s latest report* states that such impressive growth, which will occur across the eight major markets (8MM) of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, will be primarily driven by increased disease prevalence during the forecast period.
Qaisrah Khalid, Analyst for GBI Research, says Alzheimer’s disease is significantly more common in the older population and incidence rates increase rapidly after the age of 65.
Khalid comments: “The fact that people are living longer across the globe means more cases of the disease are developing, and this has posed a growing public health crisis, which represents a very serious disease burden for patients and carers alike.
“Despite the urgent need to develop more effective treatments for Alzheimer’s disease, thorough research is being carried out into understanding the disease, as its underlying pathology remains unknown.
“However, these extensive studies have helped to develop the research and development process within this indication, providing hope for the future of Alzheimer’s disease therapeutics.”
GBI Research also states that although disease prevalence will be the strongest driver of market growth, innovation in the pipeline will also be a factor.
Khalid explains: “While many of the later-stage therapies focus on common targets, the earlier stages of the pipeline do not appear to follow this trend, as they contain many first-in-class molecules with novel molecular targets within the context of Alzheimer’s disease therapeutics.
“The primary new approvals for drugs that will drive growth during the forecast period will supplement current market leaders and offer greater therapeutic options. Promising examples include verubecestat, aducanumab and azeliragon, all of which have demonstrated clinical benefit and will be approved during the forecast period.”
-ENDS-
NOTES TO EDITORS
*
Alzheimer’s Disease Therapeutics Market to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying AgentsThis report provides analysis of the Alzheimer’s disease therapeutics space across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, with annualized market data from 2014 and forecast to 2021. It includes information on the current clinical and commercial landscape, and the composition of the Alzheimer’s disease market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
ABOUT GBI RESEARCH
GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.
For further details, please Contact Us.
Latest Press Releases